Cooley LLP is a market leader in life sciences and technology offerings, including for a growing number of European, Asian and Latin American issuers. A new office in Miami has increased its connection to the Latin American market. In 2023, it continued to work on a series of IPOs and follow-on offerings by issuers in Europe and Asia. The firm has a wide-ranging and impressive client base from start-ups to growth businesses and established public companies. It is also close to key financial institutions. A force in equity offerings, it has a further presence in equity-linked transactions. San Diego-based Charlie Kim heads the capital markets team alongside David Peinsipp in San Francisco. New York’s Div Gupta and Richard Segal are also leading names.

Legal 500 Editorial commentary

Key clients

  • Abivax S.A.
  • Addex Therapeutics SA
  • Ambrx Biopharma
  • Autolus Therapeutics plc
  • Bicycle Therapeutics plc
  • Cowen and Company
  • Exscientia plc
  • Faron Pharmaceuticals Oy
  • Gamida Cell Ltd.
  • Goldman Sachs & Co. LLC
  • Gracell Biotechnologies
  • Immunocore Limited
  • J.P. Morgan Securities LLC
  • Jefferies LLC
  • Lava Therapeutics
  • Legend Biotech Corporation
  • Molecular Partners AG
  • Morgan Stanley & Co.
  • Oculis SA
  • Structure Therapeutics Inc.

Work highlights

  • Advised the underwriters on argenx SE’s $1.2bn follow-on offering.
  • Represented Abivax in its $235.8m IPO.
  • Advised Structure Therapeutics on its $185.3m IPO.

Practice head

The lawyer(s) leading their teams.

Charlie Kim, David Peinsipp

Other key lawyers

Richard Segal, Div Gupta